@article{oai:repo.qst.go.jp:00047651,
 author = {Kimura, Yasuyuki and Endo, Hironobu and Ichise, Masanori and Shimada, Hitoshi and Seki, Chie and Ikoma, Yoko and Shinotoh, Hitoshi and Yamada, Makiko and Higuchi, Makoto and Zhang, Ming-Rong and Suhara, Tetsuya and 木村 泰之 and 遠藤 浩信 and 市瀬 正則 and 島田 斉 and 関 千江 and 生駒 洋子 and 篠遠 仁 and 山田 真希子 and 樋口 真人 and 張 明栄 and 須原 哲也},
 issue = {6},
 journal = {EJNMMI research},
 month = {Mar},
 note = {Quantitative in vivo imaging of tau pathologies potentially improves diagnostic accuracy of neurodegenerative tauopathies and would facilitate evaluation of disease-modifying drugs targeting tau lesions in these diseases. Tau pathology can be quantified by reference tissue models without arterial blood sampling when reference tissue devoid of target binding sites is available. The cerebellar cortex has been used as a reference region in analyses of tau positron emission tomography (PET) data in Alzheimer's disease (AD). However, in a significant subset of tauopathies such as progressive supranuclear palsy and corticobasal degeneration, tau accumulation may occur in diverse brain regions including the cerebellar cortex. This hampers selection of a distinctive reference region lacking binding sites for a tau PET ligand. The purpose of this study was to develop a new method to quantify specific binding of a PET radioligand, (11)C-PBB3, to tau deposits using reference voxels extracted from cortical gray matter, which have a low likelihood of containing tau accumulations.},
 title = {A new method to quantify tau pathologies with (11)C-PBB3 PET using reference tissue voxels extracted from brain cortical gray matter.},
 volume = {6},
 year = {2016}
}